Fludarabine Phosphate (Fludara)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Leukemia, Lymphocytic, Chronic, B-Cell
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Trial Timeline
Nov 1, 2000 → Sep 1, 2005
NCT ID
NCT00220311About Fludarabine Phosphate (Fludara)
Fludarabine Phosphate (Fludara) is a approved stage product being developed by Sanofi for Leukemia, Lymphocytic, Chronic, B-Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT00220311. Target conditions include Leukemia, Lymphocytic, Chronic, B-Cell.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Lymphocytic, Chronic, B-Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00185445 | Phase 2 | Completed |
| NCT00688883 | Phase 2 | Completed |
| NCT00220311 | Approved | Completed |
Competing Products
20 competing products in Leukemia, Lymphocytic, Chronic, B-Cell